4.7 Article Book Chapter

External guide sequence technology: a path to development of novel antimicrobial therapeutics

期刊

ANTIMICROBIAL THERAPEUTICS REVIEWS
卷 1354, 期 -, 页码 98-110

出版社

BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12755

关键词

antisense; external guide sequence; RNase P; drug design; antimicrobials

资金

  1. VA [860065, 1028595, 5I01BX001974-06, 5I01BX001974-04] Funding Source: Federal RePORTER

向作者/读者索取更多资源

RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of precursor tRNAs (pre-tRNAs) at the 5'-end termini. RNase P is a ribonucleoprotein consisting of a catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site of cleavage of a pre-tRNA is identified by its tertiary structure; and any RNA molecule can be cleaved by RNase P as long as the RNA forms a duplex that resembles the regional structure in the pre-tRNA. When the antisense sequence that forms the duplex with the strand that is subsequently cleaved by RNase P is in a separate molecule, it is called an external guide sequence (EGS). These fundamental observations are the basis for EGS technology, which consists of inhibiting gene expression by utilizing an EGS that elicits RNase P-mediated cleavage of a target mRNA molecule. EGS technology has been used to inhibit expression of a wide variety of genes, and may help development of novel treatments of diseases, including multidrug-resistant bacterial and viral infections.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据